Completed PHASE3 INTERVENTIONAL 2-arm NCT01970098

A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

A Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Sponsor: Kissei Pharmaceutical Co., Ltd.

Interventions KPS-0373, High dose KPS-0373, Low dose Placebo

Updated 6 times since 2017 Last updated: Dec 12, 2018 Started: Oct 9, 2013 Primary completion: Jan 31, 2015 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Spinocerebellar Degeneration, this trial is completed. The trial is conducted by Kissei Pharmaceutical Co., Ltd. and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2019 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kissei Pharmaceutical Co., Ltd.

Data source: Kissei Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Multiple Locations, Japan